| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 52 | 22.5x | 17.8x | Around median | |
Growth | 63 | 14.0% | 7.1% | Around median | |
Quality | 80 | 12.2% | 4.5% | Top tier | |
Safety | 39 | 4.4x | 2.6x | Bottom tier | |
Capital Return | 45 | 0.72% | 2.12% | Around median | |
Momentum | 97 | 30.4% | 2.9% | Top tier | |
Sentiment | 37 | 6 | 3 | Bottom tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, serving more than 200 thousand small clients alongside large companies. Its core business is based on occupational health centers that provide work injury treatment and employer services, while other revenue sources include Onsite Health clinics, telemed services, pharmacy services, and services related to occupational health. The company achieves growth by increasing patient visits and revenue per visit, opening new centers, pursuing disciplined acquisitions, and expanding services with existing clients.
In fiscal Q2 2026, revenue increased 10.0% year over year to $606.0 million, and adjusted net income attributable to the company reached $66.7 million, up nearly 40% from $47.7 million, while adjusted earnings per share rose to $0.52 from $0.37. Adjusted earnings before interest, taxes, depreciation, and amortization increased 22.5% to $140.9 million, and its margin expanded by approximately 240 basis points to 23.3% from 20.9%. The cost of services also declined to 68.3% of revenue from 70.7%, while operating cash flow was $135.2 million and free cash flow was $121 million.
Occupational Health accounted for the largest portion of the fiscal Q2 2026 mix, generating revenue of $553.5 million and growth of 7.2%, including $361.2 million from work injuries and $183.2 million from employer services. Onsite Health clinics generated revenue of $38.8 million, up 72.1% overall and 27.9% excluding the impact of the Pivot acquisition, while other businesses grew 13.3% to $13.7 million. Average occupational health center visits increased to more than 56 thousand visits per day, with work injury visits growing 3.7% and employer services visits growing 1.8%.
Automated analysis for informational purposes only — not investment advice.
The average analyst price target is $38.6, above the 52-week range high of $35.9, with a “Buy” consensus. However, the wide target range of $30 to $42 reflects meaningful differences in estimates of the sustainability of visit growth and margins, and the available data do not include a valid earnings multiple that could be used as an additional valuation anchor.
Figures in the text are as of 2026-08-31; the live price is shown at the top of the page.
Concentra's revenue increased 10.0% year over year to $606.0 million, and 8% after excluding the contribution from Pivot. Occupational health center visits increased 2.6% to more than 56 thousand visits per day, while revenue per visit rose 4.6%. Combined with staffing efficiency and Nova integration savings, this helped increase adjusted earnings before interest, taxes, depreciation, and amortization by 22.5% to $140.9 million and expand its margin to 23.3%.
On August 7, 2026, the company raised its revenue range to between $2.325 billion and $2.375 billion. It also raised its adjusted earnings before interest, taxes, depreciation, and amortization range to $485–495 million and its free cash flow range to $220–240 million. It maintained its capital expenditure range at $70–80 million, assuming low-single-digit visit growth and pricing growth approaching 3% during the remainder of the year.
Onsite Health generated revenue of $38.8 million in fiscal Q2 2026, up 72.1% from the comparable period. Even after excluding the impact of Pivot, organic growth was 27.9%, faster than the growth of the core occupational health business. Management attributed this performance to the strength of the sales pipeline, expansion with existing clients, and advanced primary care services supported by the implementation of Epic, but cautioned that organic growth in the mid-to-high twenties percentage range may not continue over the long term.
The company generated $135.2 million in operating cash flow and $121 million in free cash flow in fiscal Q2 2026. It spent $11 million to repurchase approximately 424 thousand shares and paid $8 million in dividends, with approximately $54 million remaining under the original $100 million repurchase program. As of June 30, 2026, debt was $1.57 billion and cash was $158 million, while net leverage declined to just below 3 times compared with a long-term target near 2.5 times.
The company announced that Keith Newton will transition on November 1, 2026 from chief executive officer to executive chairman. On the same date, Matt DiCanio, president and chief financial officer, will become president and chief executive officer, while Bob Ortenzio will remain a member of the board of directors. Management described the change as the result of a multiyear succession plan and confirmed that the growth strategy through new centers, acquisitions, and operating leverage will remain unchanged.
The company targets opening between 8 and 10 new centers during fiscal 2026, with a list of 30 to 40 locations under evaluation. It opened a center near Phoenix during the quarter, followed by two centers in Boise and Kansas City after quarter-end, with the Boise location becoming its first center in Idaho and Idaho becoming the forty-second state in its network. Management expects that it may open more than ten locations in 2027, but explained that new centers typically require 12–24 months for their contribution to become clearly visible and that their impact on 2026 visits is less than 1%.
